Pharmacology of the EndothelinAReceptor Antagonist: LU 135252 (1998)

Cardiovascular Drug ReviewsVolume 16, Issue 4 p. 391-412 Free Access Pharmacology of the EndothelinA Receptor Antagonist: LU 135252 P. Rohmeiss, Corresponding Author P. Rohmeiss Fifth Department of Medicine, University Hospital Mannheim, University of Heidelberg, Mannheim, GermanyAddress correspondence and reprint requests to Dr. P. Rohmeiss, Fifth Department of Medicine, University Hospital Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, D-68135 Mannheim, Germany. Fax: 49-0-621-383-2049.Search for more papers by this authorR. Birck, R. Birck Fifth Department of Medicine, University Hospital Mannheim, University of Heidelberg, Mannheim, GermanySearch for more papers by this authorC. Braun, C. Braun Fifth Department of Medicine, University Hospital Mannheim, University of Heidelberg, Mannheim, GermanySearch for more papers by this authorK. Münter, K. Münter Experimental & Cardiovascular Research, Knoll AG, Ludwigshafen, GermanySearch for more papers by this authorF. J. van der Woude, F. J. van der Woude Fifth Department of Medicine, University Hospital Mannheim, University of Heidelberg, Mannheim, GermanySearch for more papers by this authorM. Kirchengast, M. Kirchengast Experimental & Cardiovascular Research, Knoll AG, Ludwigshafen, GermanySearch for more papers by this author P. Rohmeiss, Corresponding Author P. Rohmeiss Fifth Department of Medicine, University Hospital Mannheim, University of Heidelberg, Mannheim, GermanyAddress correspondence and reprint requests to Dr. P. Rohmeiss, Fifth Department of Medicine, University Hospital Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, D-68135 Mannheim, Germany. Fax: 49-0-621-383-2049.Search for more papers by this authorR. Birck, R. Birck Fifth Department of Medicine, University Hospital Mannheim, University of Heidelberg, Mannheim, GermanySearch for more papers by this authorC. Braun, C. Braun Fifth Department of Medicine, University Hospital Mannheim, University of Heidelberg, Mannheim, GermanySearch for more papers by this authorK. Münter, K. Münter Experimental & Cardiovascular Research, Knoll AG, Ludwigshafen, GermanySearch for more papers by this authorF. J. van der Woude, F. J. van der Woude Fifth Department of Medicine, University Hospital Mannheim, University of Heidelberg, Mannheim, GermanySearch for more papers by this authorM. Kirchengast, M. Kirchengast Experimental & Cardiovascular Research, Knoll AG, Ludwigshafen, GermanySearch for more papers by this author First published: 02 April 2007 https://doi.org/10.1111/j.1527-3466.1998.tb00365.xCitations: 9AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Alberts GF, Peifley KA, Johns A, Kleha JF, Winkles JA. Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop. J Biol Chem 1994; 269: 10112–10118. 2 Amann K, Münter K, Wagner J, et al. Reduction of capillary supply is prevented by a selective endothelin receptor antagonist (ETA-RA) in a model of left ventricular hypertrophy. Circulation 1998 (submitted). 3 Barton M, D'Uscio LV, Shaw SG, Haudenschild CC, Lüscher TF. Chronic selective ETA-receptor blockade inhibits atherosclerosis and endothelial dysfunction in ApoE-knockout mice. Eur Heart J 1998; 19: 13. 4 Barton M, D'Uscio LV, Shaw SG, Meyer P, Moreau P, Lüscher TF. ETA-receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy and endothelial dysfunction in salt-sensitive hypertension. Hypertension 1998; 31: 499–504. 5 Barton M, D'Uscio LV, Shaw SG, Moreau P, Lüscher TF. An orally available ETA antagonist prevents renal artery dysfunction in salt-induced hypertension. Circ Res 1998 (submitted). 6 Barton M, Haudenschild CC, D'Uscio LV, Shaw SG, Mùnter K, Lüscher TF. Endothelin blockade inhibits atherosclerosis and restores endothelial function. Proc Natl Acad Sci USA 1998; 95: 14367–14372. 7 Barton M, Shaw SG, D'Uscio LV, Moreau P, Lüscher TF. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin-converting enzyme activity in vivo: Role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun 1997; 238: 861–865. 8 Barton M, Shaw SG, D'Uscio LV, Moreau P, Lüscher TF. Differential modulation of the renal and myocardial endothelin system by angiotensin D in vivo: Effects of chronic selective ETA-receptor blockade. J Cardiovasc Pharmacol 1998; 31: S265–S269. 9 Benigni A, Corna D, Maffi R, Benedetti G, Zoja C, Remuzzi G. Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. Kidney Int 1998; 54: 353–359. 10 Berthold H, Münter K, Just A, Kirchheim HR, Ehmke H. Contribution of endogenous endothelin to the regulation of systemic and renal hemodynamics and its interaction with the renin-angiotensin system. Pflügers Arch Eur J Physiol 1998; 435: R86. 11 Berthold H, Münter K, Just A, Kirchheim HR, Ehmke H. Contribution of endothelin to renal vascular tone and autoregulation in the conscious dog. Am J Physiol 1998 (in press). 12 Birck R, Knoll T, Braun C, Gretz N, van der Woude, FJ, Rohmeiss P. Improvement of acute renal failure (ARF) in rats by the oral endothelin-A-receptor (ET-A) antagonist LU 135252. J Hypertens 1997; 15: S27. 13 Birck R, Knoll T, Braun C, et al. Improvement of postischemic acute renal failure with the novel orally active endothelin-A-receptor antagonist LU 135252 in the rat. J Cardiovasc Pharmacol 1998; 32: 80–86. 14 Boulanger CM, Lüscher TF. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 1990; 85: 587–590. 15 Brady HR, Singer GG. Acute renal failure. Lancet 1995; 346: 1533–1540. 16 Braun C, Conzelmann T, Vetter S, et al. Important role of the endothelin system in chronic rejection of renal allografts in rats. Transplantation 1998; 98: 248. 17 Braun C, Conzelmann T, Vetter S, et al. Prevention of chronic renal allograft rejection in rats with an oral endothelin-A-receptor antagonist. Transplantation (submitted). 18 Brochu E, Lacasse-M S, Larivière R, Kingma I, Lebel M. Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure rats. J Hypertens 1998; 16: S90. 19 Brochu E, Moreau C, Lebel M, Kingma I, Grose JH, Lanivière R. Endothelin (ET)A-receptor blockade prevents worsening of hypertension in rats with chronic renal failure. J Hypertens 1998; 16: S100. 20 Cernacek P, Strmen J, Levy M. Acute renal effects of ETA blockade: Interspecies differences. J Cardiovasc Pharmacol 1997; 31: S269–S272. 21 Cohn JN, Archibald D, Ziesche S. Effects of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986; 314: 1547–1552. 22 Cohn JN, Johnson G, Ziesche S. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of congestive heart failure. N Engl J Med 1991; 325: 303–310. 23 D'Uscio LV, Barton M, Shaw SG, Moreau P, Lüscher TF. Structure and function of small arteries in salt-induced hypertension. Effects of chronic ETA-receptor blockade. Hypertension 1997; 30: 905–911. 24 D'Uscio LV, Moreau P, Shaw SG, Takase H, Barton M, Lüscher TF. Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension. Hypertension 1997; 29: 435–441. 25 Dashwood MR, Münter K, Kirchengast M. Endothelin-1 (ET-1) and its receptors in porcine coronary artery: Effect of balloon angioplasty. J Mol Cell Cardiol 1997; 29: 242. 26 Dashwood MR, Nörtersheuser P, Kirchengast M, Münter K. Altered endothelin-1 binding following balloon angioplasty of pig coronary arteries: Effect of the ETA-receptor antagonist, LU 135252. Cardiovasc Res 1998 (submitted). 27 Ehmke H, Faulhaber J, Münter K, Kirchengast M, Wiesner RJ. Differential alteration of left ventricular hypertrophy and fetal gene expression by endothelin ETA-receptor inhibition in rats with renal artery stenosis. Hypertension 1998 (submitted). 28 Ehmke H, Faulhaber J, Wiesner RJ. Cardiac hypertrophy and reexpression of fetal phenotype in rats: Role of endothelin-A receptors. Pflügers Arch Eur J Physiol 1996; 431: R41. 29 Foitzik T, Faulhaber J, Hotz HG, Kirchengast M, Buhr HJ. Endothelin-receptor blockade enhances impaired pancreatic capillary blood flow in experimental acute pancreatitis. Int J Microcirc 1996; 16: 135. 30 Foitzik T, Faulhaber J, Hotz HG, Kirchengast M, Buhr HJ. Endothelin-1 mediates the alcohol-induced reduction of pancreatic capillary blood flow. J Gastrointest Surg 1988 (in press). 31 Foitzik T, Faulhaber J, Hotz HG, Kirchengast M, Buhr HJ. Endothelin-receptor blockade reduces fluid sequestration, enhances impaired capillary blood flow and improves survival in acute pancreatitis in the rat. Ann Surg 1988 (in press). 32 Foitzik T, Hotz HG, Faulhaber J, Kirchengasl M, Buhr HJ. Endothelin-receptor blockade improves survival in acute experimental pancreatitis. Pancreas 1996; 13: 436. 33 Foitzik T, Hotz HG, Faulhaber J, Kirchengast M, Buhr HJ. Endothelin-1 mediates the development of severe pancreatitis. Gastroenterology 1997; 112: A439. 34 Foitzik T, Hotz HG, Hotz B, Kirchengast M, Buhr HJ. Endothelin-1 mediates the alcohol-induced reduction of pancreatic capillary blood flow. Gastroenterology 1997; 112: A1441. 35 Folts JD, Crowell EB, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 365–370. 36 Fujisaki H, Ito H, Hirata Y, et al. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest 1995; 96: 1059–1065. 37 Gonon AT, Wang Q-D, Pemow J. The endothelin A-receptor antagonist LU 135252 protects the myocardium from neutrophil injury during ischaemia/reperfusion. Cardiovasc Res 1998; 39: 674–682. 38 Gonon AT, Wang Q-D, Shimizu M, Pernow J. The novel non-peptide selective endothelin-A-receptor antagonist LU 135252 protects from myocardial ischemic and reperfusion injury in the pig. Acta Physiol Scand 1998; 163: 131–137. 39 Gray GA, Webb DJ. The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Ther 1996; 2: 109–148. 40 Hergenröder S, Münter K, Kirchengast M. Effects of endothelin and endothelin receptor antagonist in arteriolar and venular microcirculation. Vasa 1998; 27: 216–219. 41 Hocher B, Lun A, Priem F, Neumayer HH, Raschack M. Renal endothelin system in diabetes: Comparison of angiotensin-converting enzyme inhibition and endothelin-A antagonist. J Cardiovasc Pharmacol 1998; 31: S492–S495. 42 Hocher B, Thöne-Reineke C, Bauer C, Raschack M, Neumayer HH. The paracrine endothelin system: Pathophysiology and implications in clinical medicine. Eur J Clin Chem Clin Biochem 1997; 35: 175–189. 43 Hunley TE, Kon V. Endothelin in ischemic acute renal failure. Curr Opin Nephrol Hypertens 1997; 6: 394–400. 44 Iglarz M. Matrougui K, Lévy BI, Henrion D. Chronic blockade of endothelin ETA receptors improves flow-dependent dilatation in resistance arteries of hypertensive rats. Cardiovasc Res 1998; 39: 657–664. 45 Kirchengast M, Hergenroder S, Schult S, Münter K, Rübsamen K. Endothelin-1 and unstable angina: Effect of either ETA-or ETB-receptor antagonist in a locally injured canine coronary artery. Eur J Pharmacol 1998; 341: 187–190. 46 Kirchengast M, Münter K. Endothelin and restenosis. Cardiovasc Res 1998; 39: 550–555. 47 Køber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the ACE-inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670–1676. 48 Kohan DE. Endothelins in the normal and diseased kidney. Am J Kidney Disease 1997; 1: 2–26. 49 Kon V, Yoshioka T, Fogo A, Ichikava I. Glomerular actions of endothelin in vivo. J Clin Invest 1989; 83: 1762–1767. 50 Krum H, Viskoper RJ, Lacourciere Y, et al. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Eng J Med 1998; 338: 784–790. 51 Kucher K, Nörtersheuser P, Dübbers K, Kern R. First information on the tolerability, pharmacokinetics, and pharmacodynamics of the endothelin-receptor antagonist LU 135252 in healthy human subjects. Hospitalis 1998; 68: 23S. 52 Love MP, McMurray JJV. Endothelin in chronic heart failure: current position and future prospects. Cardiovasc Res 1996; 31: 665–674. 53 Münter K, Ehmke H, Kirchengast M. Maintenance of blood pressure in normotensive dogs by endothelin-1. Am J Physiol 1998 (in press). 54 Münter K, Hergenröder S, Kirchengast M. ETA-receptor antagonism combined with hydralazine improves survival and renal function in hypertensive rats. J Cardiovasc Pharmacol 1997; 31: S245–S248. 55 Münter K, Hergenröder S, Kirchengast M. Synergistic effect of the ACE-inhibitor trandolapril and the endothelin (ETA)-receptor antagonist LU 135252. Eur Heart J 1997; 18: 87. 56 Münter K, Hergenröder S, Kirchengast M. Chronic effects of ACE-inhibition and endothelin (ETA)-receptor antagonism on blood pressure. Am J Hypert 1998; 11: 31A. 57 Münter K, Hergenröder S, Unger L, Kirchengast M. Oral treatment with an ETA-receptor antagonist inhibits neointima formation induced by endothelial injury. Pharm Pharmacol Lett 1996; 6: 90–92. 58 MacKenzie HS, Brenner BM. Current strategies for retarding progression of renal disease. Am J Kidney Disease 1998; 31: 161–170. 59 Michael KA, Parnell KJ. Innovations in the pharmacologic management of heart failure. AACN Clin Issues 1998; 9: 172–191. 60 Moe GW, Albernaz A, Naik GO, Kirchengast M, Stewart DJ. Beneficial hemodynamic effects of long-term selective endothelin type A-receptor blockade in canine experimental heart failure. Cardiovasc Res 1998; 39: 571–579. 61 Moreau P, D'Uscio LV, Shaw SG, Takase H, Barton M, Lüscher TF. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: Reversal by ETA-receptor antagonist. Circulation 1997; 96: 1593–1597. 62 Moreland SD, McMullen DM, Abboa-Offei B, Seymour A. Evidence for a differential location of vasoconstrictor endothelin receptors in the vasculature. Br J Pharmacol 1994; 112: 704–708. 63 Moreland SD, McMullen DM, Delaney CL, Lee VG, Hunt JT. Venous smooth muscle contains vasoconstrictor ETB-like receptors. Biochem Biophys Res Commun 1992; 184: 100–106. 64 Mulder P, Richard V, Bouchart F, Derumeaux G, Munter K, Thuillez C. Selective ETA-receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure. Cardiovasc Res 1998; 39: 600–608. 65 Mulder P, Richard V, Münter K, Thuillez C. Effects of the selective ETA antagonist LU 135252 on ventricular hemodynamics and remodeling in a rat model of chronic heart failure. Hospitalis 1998; 68: 24S. 66 Nabokov A, Amann K, Wagner J, Gehlen F, Münter K, Ritz E. Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation. Nephrol Dial Transplant 1996; 11: 514–520. 67 Nguyen QT, Cernacek P, Calderoni A, et al. Endothelin-A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. Circulation 1998; 98: 2323–2330. 68 Ohno A, Naruse M, Kato S, et al. Endothelin-specific antibodies decrease blood pressure and increase glomerular filtration rate and renal plasma flow in SHR. J Hypertens 1992; 10: 781–785. 69 Orth SR, Esslinger JP, Amann K, Schwarz U, Raschack M, Ritz E. Nephroprotection of an ETA-receptor blocker (LU 135252) in salt-loaded uninephrectomized SHRSP. Hypertension 1997; 31: 995–1001. 70 Pernow J, Wang Q-D. Endothelin in myocardial ischemia and reperfusion. Cardiovasc Res 1997; 33: 518–526. 71 Pfeffer JM, Finn PV, Pfeffer MA. Endothelin-A-receptor antagonism in rats with myocardial infarction and failure. J Am Coll Cardiol 1997; 29: 399A. 72 Prié S, Ki Leung T, Cernacek P, Ryan JW, Dupuis J. The orally active ETA-receptor antagonist (+)-(S)-2-(4,6-dimethyoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphenyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats. J Pharmacol Exp Ther 1997; 282: 1312–1318. 73 Prié S, Stewart DJ, Dupuis J. ETA receptor blockade improves nitric oxide-mediated vasodilation in monocrotaline-induced pulmonary hypertension. Circulation 1997; 97: 2169–2174. 74 Raschack M, Juchelka F, Rozek-Schäfer G. The endothelin-A antagonist LU 135252 suppresses ischemic ventricular extrasystoles and fibrillation in pigs and prevents hypoxic cellular decoupling. J Cardiovasc Pharmacol 1998; 31: S145–S148. 75 Raschack M, Unger L, Riechers H, Klinge D. Receptor selectivity of endothelin antagonists and prevention of vasoconstriction and endothelin-induced sudden death. J Cardiovasc Pharmacol 1995; 26: S397–S399. 76 Riechers H, Albrecht H-P, Amberg W, et al. Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A-receptor antagonists. J Med Chem 1996; 39: 2123–2128. 77 Rohmeiss P, Birck R, Braun C, Kirchengast M, van der Woude, FJ. Targets for endothelin in the diseased kidney: Clues for therapeutic intervention. Exp Nephrol 1999; 7: 1–10. 78 Rubanyi GM, Polokoff MA. Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994; 46: 325–415. 79 Schiffrin EL, Turgeon A, Deng LY. Effect of chronic ETA-selective endothelin-receptor antagonism on blood pressure in experimental and genetic hypertension in rats. Br J Pharmacol 1997; 121: 935–940. 80 Schirger JA, Chen HH, Lisy O, et al. Augmentation of cardiovascular and renal hemodynamics with ETA-receptor antagonism in severe experimental heart failure. Hospitalis 1998; 68: 25S. 81 Sharifi AM, Schiffrin EL. Apoptosis in aorta of deoxycorticosterone acetate-salt hypertensive rats: Effect of endothelin-receptor antagonism. J Hypertens 1997; 15: 1441–1448. 82 Simonson MS, Herman WH. Protein kinase C and protein tyrosine kinase activity contribute to mitogenic signaling by endothelin-1 : Cross-talk between G protein-coupled receptors and pp60c-src. J Biol Chem 1993; 268: 9347–9357. 83 Watanabe T, Suzuki N, Shimamoto N, Fujino M, Imada A. Endothelin in myocardial infarction. Nature 1990; 344: 114. 84 Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411–415. 85 Zoja C, Morigi M, Figliuzzi M, et al. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am J Kidney Dis 1995; 26: 934–941. Citing Literature Volume16, Issue4December 1998Pages 391-412 ReferencesRelatedInformation